WallStSmart
ENVB

Enveric Biosciences Inc

NASDAQ: ENVB · HEALTHCARE · BIOTECHNOLOGY

$3.95
-23.45% today

Updated 2026-04-30

Market cap
$10.01M
P/E ratio
P/S ratio
0.08x
EPS (TTM)
$-36.24
Dividend yield
52W range
$2 – $18
Volume
5.0M

WallStSmart proprietary scores

29
out of 100
Grade: F
Strong Sell
Investment rating
3.7
Growth
D
5.3
Quality
C+
3.0
Profitability
D
5.0
Valuation
C+
2/9
Piotroski F-Score
Weak
-56.4
Altman Z-Score
Distress
Industry rank
View all highly rated stocks (75+) →206 stocks currently score above 75

Price targets

Analyst target
$10.00
+153.16%
12-Month target
Intrinsic (DCF)
Margin of safety

Price chart

X-Ray snapshot

Strengths
Insufficient data
Risks
- Piotroski 2/9 — weak financial health
- Altman Z -56.44 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-1.78M
- Revenue declining -7.30% QoQ

Key financials

Revenue Net Income Free Cash Flow
Metric2022202320242025TTM
Revenue$0.00$0.00$0.00$0.00$35.41M
Net income$-18.50M$-17291.00$-9.57M$-12.13M$-2.19M
EPS$-36.24
Free cash flow$-17.73M$-14.10M$-7.73M$-8.14M$-1.78M
Profit margin

Peer comparison

CompanyMkt CapScoreGrowthProfitValueQualityMoSRating
ENVB$10.01M293.73.05.05.3Avoid
LLY$760.43B7810.010.05.06.5Strong Buy
JNJ$547.28B594.79.03.36.0-43.54%Buy
ABBV$360.63B634.08.04.75.0-29.31%Buy
UNH$336.47B545.35.57.34.8+42.09%Buy
AZN$287.11B646.78.05.35.0+4.07%Buy

Smart narrative

Enveric Biosciences Inc trades at $3.95. Our Smart Value Score of 29/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of -56.44, it sits in the distress. TTM revenue stands at $35.41M.

Frequently asked questions

What is Enveric Biosciences Inc's stock price?
Enveric Biosciences Inc (ENVB) trades at $3.95.
Is Enveric Biosciences Inc overvalued?
Smart Value Score 29/100 (Grade F, Strong Sell).
What is the price target of Enveric Biosciences Inc (ENVB)?
The analyst target price is $10.00, representing +153.2% upside from the current price of $3.95.
What is Enveric Biosciences Inc's revenue?
TTM revenue is $35.41M.
Piotroski F-Score?
2/9 — weak financial health.
Altman Z-Score?
-56.44 — distress.

Company info

SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD

Quick metrics

P/S ratio0.08x
ROE-304.00%
Beta0.33
50D MA$2.24
200D MA$6.87
Shares out0.00B
Float0.00B
Short ratio
Avg volume5.0M

Performance

1 week
1 month
3 months
YTD
1 year
3 years
5 years